Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Oxford Nanopore Technologies PLC on Friday said it reached an ‘amicable’ agreement with the UK government over a contract dispute related to the supply of Covid-19 testing services.
The contract, sealed at the end of July 2020, was for the provision of LamPORE devices and testing kits to the UK Department of Health & Social Care.
Oxford Nanopore will receive a £50 million payment as part of the resolution of the dispute.
The amount will be treated as ‘non-recurring Covid-19 testing revenue’ for 2022. As a result, its guidance for its Life Science Research Tools remains unchanged.
In its annual results reported in March, Oxford Nanopore said it had concluded its Covid-19 diagnostics offerings, due to the greater availability of PCR tests and as the pandemic moved ‘towards an endemic phase’. At the time, it said a deal with the DHSC had concluded.
For 2022, Oxford Nanopore expects Life Science Research Tools revenue of between £145 million and £160 million, at best, up by over a quarter from 2021. This is tipped to rise further to between £190 million to £220 million in 2023.
Shares in the company were 1.4% lower at 392.54 pence each in London on Friday morning.
Copyright 2022 Alliance News Limited. All Rights Reserved.